Prevalence of postpartum thyroid dysfunction: A quantitative review

Wanda K. Nicholson, Karen A Robinson, Robert C. Smallridge, Paul W Ladenson, Neil R. Powe

Research output: Contribution to journalArticle

Abstract

Estimates of the prevalence of postpartum thyroid dysfunction (PPTD) vary widely because of variations in study design, populations, and duration of screening. Our objective was to estimate the prevalence of PPTD among general and high-risk women, across geographical regions and in women with antithyroid peroxidase antibodies (TPOAbs). We conducted a systematic review and pooled analysis of the published literature (1975-2004), simultaneously accounting for sample size, study quality, percentage follow-up, and duration of screening. Data sources were MEDLINE and the bibliography of candidate studies. Two reviewers independently extracted data. Of 587 studies identified, 21 articles (8081 subjects) met the study criteria. The pooled prevalence of PPTD, defined as an abnormal thyroid-stimulating hormone (TSH) level, for the general population was 8.1% (95% confidence interval [CI] 6.6%-10.0%). The risk ratios for the development of PPTD among women with TPOAbs compared to women without TPOAbs ranged between 4 and 97 with a pooled risk ratio of 5.7 (95% CI: 5.3-6.1). Global prevalence varied from 4.4% in Asia to 5.7% in the United States. Prevalence among women with type 1 diabetes mellitus was 19.6% (95% CI 19.5%-19.7%). PPTD occurs in 1 of 12 women in the general population worldwide, 1 of 17 women in the United States and is 5.7 times more likely to occur in women with TPOAbs. The high prevalence may warrant routine screening TPOAbs, but the benefits, cost, and risks related to subsequent therapy must be weighed.

Original languageEnglish (US)
Pages (from-to)573-582
Number of pages10
JournalThyroid
Volume16
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

Postpartum Period
Thyroid Gland
Confidence Intervals
Odds Ratio
Population
Information Storage and Retrieval
Bibliography
Thyrotropin
Type 1 Diabetes Mellitus
MEDLINE
Sample Size
Peroxidase
Cost-Benefit Analysis
Antibodies

ASJC Scopus subject areas

  • Endocrinology

Cite this

Prevalence of postpartum thyroid dysfunction : A quantitative review. / Nicholson, Wanda K.; Robinson, Karen A; Smallridge, Robert C.; Ladenson, Paul W; Powe, Neil R.

In: Thyroid, Vol. 16, No. 6, 06.2006, p. 573-582.

Research output: Contribution to journalArticle

Nicholson, Wanda K. ; Robinson, Karen A ; Smallridge, Robert C. ; Ladenson, Paul W ; Powe, Neil R. / Prevalence of postpartum thyroid dysfunction : A quantitative review. In: Thyroid. 2006 ; Vol. 16, No. 6. pp. 573-582.
@article{2a72e132835f4da9b33a5d9cd7a8d8d1,
title = "Prevalence of postpartum thyroid dysfunction: A quantitative review",
abstract = "Estimates of the prevalence of postpartum thyroid dysfunction (PPTD) vary widely because of variations in study design, populations, and duration of screening. Our objective was to estimate the prevalence of PPTD among general and high-risk women, across geographical regions and in women with antithyroid peroxidase antibodies (TPOAbs). We conducted a systematic review and pooled analysis of the published literature (1975-2004), simultaneously accounting for sample size, study quality, percentage follow-up, and duration of screening. Data sources were MEDLINE and the bibliography of candidate studies. Two reviewers independently extracted data. Of 587 studies identified, 21 articles (8081 subjects) met the study criteria. The pooled prevalence of PPTD, defined as an abnormal thyroid-stimulating hormone (TSH) level, for the general population was 8.1{\%} (95{\%} confidence interval [CI] 6.6{\%}-10.0{\%}). The risk ratios for the development of PPTD among women with TPOAbs compared to women without TPOAbs ranged between 4 and 97 with a pooled risk ratio of 5.7 (95{\%} CI: 5.3-6.1). Global prevalence varied from 4.4{\%} in Asia to 5.7{\%} in the United States. Prevalence among women with type 1 diabetes mellitus was 19.6{\%} (95{\%} CI 19.5{\%}-19.7{\%}). PPTD occurs in 1 of 12 women in the general population worldwide, 1 of 17 women in the United States and is 5.7 times more likely to occur in women with TPOAbs. The high prevalence may warrant routine screening TPOAbs, but the benefits, cost, and risks related to subsequent therapy must be weighed.",
author = "Nicholson, {Wanda K.} and Robinson, {Karen A} and Smallridge, {Robert C.} and Ladenson, {Paul W} and Powe, {Neil R.}",
year = "2006",
month = "6",
doi = "10.1089/thy.2006.16.573",
language = "English (US)",
volume = "16",
pages = "573--582",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Prevalence of postpartum thyroid dysfunction

T2 - A quantitative review

AU - Nicholson, Wanda K.

AU - Robinson, Karen A

AU - Smallridge, Robert C.

AU - Ladenson, Paul W

AU - Powe, Neil R.

PY - 2006/6

Y1 - 2006/6

N2 - Estimates of the prevalence of postpartum thyroid dysfunction (PPTD) vary widely because of variations in study design, populations, and duration of screening. Our objective was to estimate the prevalence of PPTD among general and high-risk women, across geographical regions and in women with antithyroid peroxidase antibodies (TPOAbs). We conducted a systematic review and pooled analysis of the published literature (1975-2004), simultaneously accounting for sample size, study quality, percentage follow-up, and duration of screening. Data sources were MEDLINE and the bibliography of candidate studies. Two reviewers independently extracted data. Of 587 studies identified, 21 articles (8081 subjects) met the study criteria. The pooled prevalence of PPTD, defined as an abnormal thyroid-stimulating hormone (TSH) level, for the general population was 8.1% (95% confidence interval [CI] 6.6%-10.0%). The risk ratios for the development of PPTD among women with TPOAbs compared to women without TPOAbs ranged between 4 and 97 with a pooled risk ratio of 5.7 (95% CI: 5.3-6.1). Global prevalence varied from 4.4% in Asia to 5.7% in the United States. Prevalence among women with type 1 diabetes mellitus was 19.6% (95% CI 19.5%-19.7%). PPTD occurs in 1 of 12 women in the general population worldwide, 1 of 17 women in the United States and is 5.7 times more likely to occur in women with TPOAbs. The high prevalence may warrant routine screening TPOAbs, but the benefits, cost, and risks related to subsequent therapy must be weighed.

AB - Estimates of the prevalence of postpartum thyroid dysfunction (PPTD) vary widely because of variations in study design, populations, and duration of screening. Our objective was to estimate the prevalence of PPTD among general and high-risk women, across geographical regions and in women with antithyroid peroxidase antibodies (TPOAbs). We conducted a systematic review and pooled analysis of the published literature (1975-2004), simultaneously accounting for sample size, study quality, percentage follow-up, and duration of screening. Data sources were MEDLINE and the bibliography of candidate studies. Two reviewers independently extracted data. Of 587 studies identified, 21 articles (8081 subjects) met the study criteria. The pooled prevalence of PPTD, defined as an abnormal thyroid-stimulating hormone (TSH) level, for the general population was 8.1% (95% confidence interval [CI] 6.6%-10.0%). The risk ratios for the development of PPTD among women with TPOAbs compared to women without TPOAbs ranged between 4 and 97 with a pooled risk ratio of 5.7 (95% CI: 5.3-6.1). Global prevalence varied from 4.4% in Asia to 5.7% in the United States. Prevalence among women with type 1 diabetes mellitus was 19.6% (95% CI 19.5%-19.7%). PPTD occurs in 1 of 12 women in the general population worldwide, 1 of 17 women in the United States and is 5.7 times more likely to occur in women with TPOAbs. The high prevalence may warrant routine screening TPOAbs, but the benefits, cost, and risks related to subsequent therapy must be weighed.

UR - http://www.scopus.com/inward/record.url?scp=33746005905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746005905&partnerID=8YFLogxK

U2 - 10.1089/thy.2006.16.573

DO - 10.1089/thy.2006.16.573

M3 - Article

C2 - 16839259

AN - SCOPUS:33746005905

VL - 16

SP - 573

EP - 582

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 6

ER -